Globenewswire·2026-02-28 07:12Core Viewpoint - Fangzhou Inc. has entered a strategic collaboration with Youcare Pharmaceutical Group to enhance chronic disease services through AI-driven solutions, aiming to support China's digital transformation in healthcare [1][2][8] Group 1: Partnership Objectives - The collaboration focuses on two main areas: co-development of digital systems for chronic disease management and expansion of health management services in key therapeutic areas [6][4] - The partnership aims to integrate Youcare's pharmaceutical expertise with Fangzhou's AI capabilities to create a digitally enabled chronic disease management system [6][4] Group 2: Industry Context - China's chronic disease management is shifting from a drug-centered model to a patient-centered approach, necessitating digital transformation in healthcare services [3][8] - The partnership aligns with China's "Healthy China 2030" initiative, emphasizing the importance of integrating AI technology with chronic disease services and pharmaceutical innovation [8][7] Group 3: Company Profiles - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025, specializing in AI-enabled precision medicine [9] - Youcare Pharmaceutical Group is a large-scale conglomerate in the pharmaceutical industry, focusing on drug R&D, manufacturing, and distribution, and is recognized as one of the top 100 enterprises in China [10]